15-Hydroxy-5,8,11,13-eicosatetraenoic acid | 73945-47-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 15-Hydroxy-5,8,11,13-eicosatetraenoic acid
• 英文别名: (5E,8E,11E,13E)-15-hydroxyicosa-5,8,11,13-tetraenoic acid
• CAS: 73945-47-8
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: JSFATNQSLKRBCI-NLORQXDXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  15-Hydroxy-5,8,11,13-eicosatetraenoic acid 、 重氮甲烷 生成 methyl (5E,8E,11E,13E)-15-hydroxyicosa-5,8,11,13-tetraenoate
  参考文献：
  名称：

  HAWKINS, DAN J.;KUHN, HARTMUT;PETTY, ERIC H.;BRASH, ALAN R., ANAL. BIOCHEM., 173,(1988) N 2, C. 456-462

  摘要：

  DOI：
• 作为产物：
  描述：

  (5E,8E,11E,14E)-(114C)icosa-5,8,11,14-tetraenoic acid 生成 15-Hydroxy-5,8,11,13-eicosatetraenoic acid
  参考文献：
  名称：

  KIMURA, YOSHIYUKI;OKUDA, HIROMICHI;OKUDA, TAKUO;HATANO, TSUTOMU;ARICHI, S+, J. NATUR. PROD., 50,(1987) N 3, 392-399

  摘要：

  DOI：

文献信息

• [EN] PHARMACEUTICALLY ACCEPTABLE SALTS OF POLYUNSATURATED HYDROXY FATTY ACIDS<br/>[FR] SELS ACCEPTABLES SUR LE PLAN PHARMACEUTIQUE D'ACIDES GRAS HYDROXYLÉS POLYINSATURÉS
  申请人：DIGNITY SCIENCES LTD

  公开号：WO2015071766A1

  公开（公告）日：2015-05-21

  The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.

  本公开提供了15-脂氧合酶产物的药用可接受的稳定盐形式，例如15-HETrE赖氨酸盐，包括相同盐的组合物以及制备和使用相同盐的方法。
• Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
  申请人：——

  公开号：US20010051648A1

  公开（公告）日：2001-12-13

  Heteroatom-interrupted HETE derivatives and methods of their use for treating dry eye are disclosed.

  插入杂原子的HETE衍生物及其用于治疗干眼症的方法被披露。
• BETA LACTAMS AS ANTIPROLIFERATIVE AGENTS
  申请人：——

  公开号：US20020082250A1

  公开（公告）日：2002-06-27

  This invention relates to a method of treating or reducing cell proliferation in a mammal in need thereof which comprises administering to said mammal an effective CoA-independent transacylase (CoA-IT) inhibiting amount of a compound of formula (I), wherein the variables of Y, X, m, R 3, R 4, R 10, R 20, R 5, R 6 and R 7 are defined in the specification. FIG. 3 demonstrates the ability of SB216754, ((3S,4R)-4-(isobutenyloxy)-3-triphenylmethylamino)azetidin-2-one) to decrease the viability of HL-60 cells.

  这项发明涉及一种治疗或减少哺乳动物细胞增殖的方法，包括向该哺乳动物施用化合物（I）的有效CoA独立转酰基酶（CoA-IT）抑制量，其中化合物的Y、X、m、R 3、R 4、R 10、R 20、R 5、R 6和R 7的变量在说明书中定义。图3展示了SB216754（（3S,4R)-4-(异丁烯氧基)-3-三苯甲基氨基)吖唑啉-2-酮）降低HL-60细胞存活能力的能力。
• Compounds and methods for treatment of asthma, allergy and inflammatory disorders
  申请人：UCB S.A.

  公开号：US20030220347A1

  公开（公告）日：2003-11-27

  The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.

  本发明提供了1,4-取代哌嗪、1,4-取代哌啶和1-取代、4-烷基亚烯基哌啶化合物。本发明的化合物是具有白三烯抑制性和抗组胺性的双重作用分子。本发明的化合物用于治疗可能存在组胺和/或白三烯成分的病症。这些病症包括哮喘、季节性和全年性过敏性鼻炎、鼻窦炎、结膜炎、食物过敏、鲭鱼中毒、牛皮癣、荨麻疹、瘙痒、湿疹、类风湿性关节炎、炎症性肠病、慢性阻塞性肺疾病、血栓性疾病和中耳炎。还提供了通过向需要治疗哮喘和鼻炎的受试者施用有效的缓解哮喘和鼻炎的化合物量的方法。
• Skin treatment compositions
  申请人：UNILEVER N.V.

  公开号：EP0097059A2

  公开（公告）日：1983-12-28

  A composition suitable for topical application to human skin comprises, in addition to a suitable vehicle and a perfume, an active ingredient which can control skin barrier functions. The active ingredient is (a) a long chain ω-hydroxy fatty acid or a carboxy-substituted derivative, (b) an hydroxy- or epoxy- derivative of an essential fatty acid or an ester formed between (a) and (b). Certain novel compounds of structures (a), (b) and (a) (b) esters are also claimed.

  一种适用于人体皮肤局部施用的组合物，除含有适当的载体和香料外，还含有 一种可控制皮肤屏障功能的活性成分。活性成分是：(a) 长链ω-羟基脂肪酸或羧基取代的衍生物；(b) 必需脂肪酸的羟基或环氧衍生物或(a)和(b)之间形成的酯。本发明还要求得到结构为(a)、(b)和(a)(b)酯的某些新型化合物。